Novogen Limited (NASDAQ:KZIA) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of Novogen Limited (NASDAQ:KZIA) have been given an average recommendation of “Moderate Buy” by the seven ratings firms that are currently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating and six have issued a buy rating on the company. The average 1-year price objective among brokers that have covered the stock in the last year is $27.3333.

KZIA has been the topic of a number of research reports. BTIG Research restated a “buy” rating and issued a $40.00 price objective on shares of Novogen in a report on Thursday, September 10th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Novogen in a report on Friday, July 17th. Canaccord Genuity Group initiated coverage on shares of Novogen in a report on Thursday, August 13th. They issued a “buy” rating and a $29.00 price target on the stock. Finally, Lake Street Capital assumed coverage on shares of Novogen in a research report on Thursday, June 11th. They set a “buy” rating and a $32.00 price target on the stock.

Novogen Stock Down 4.3%

Shares of KZIA stock opened at $10.39 on Friday. Novogen has a one year low of $4.86 and a one year high of $17.40. The company has a 50 day moving average price of $12.86 and a 200 day moving average price of $11.79.

Novogen Company Profile

Novogen Limited, now known as Kazia Therapeutics Limited, is an Australia-based biotechnology company focused on developing therapies for cancer and other serious diseases. The company’s research has centered on targeted treatments designed to address tumors that are difficult to treat with conventional approaches.

Kazia’s principal clinical program has been paxalisib, an orally administered inhibitor of the PI3K/mTOR pathway being investigated primarily for brain cancers, including glioblastoma.